

Table SI. Rat usage and mortality of experiment 1.

| Groups   | Usage of the rats, n |                    | Number of deaths in rats | Mortality, % (n/total n) | Excluded |
|----------|----------------------|--------------------|--------------------------|--------------------------|----------|
|          | Western blot         | Immunofluorescence |                          |                          |          |
| Sham     | 6                    | 2                  | 0                        | 0.0 (0/8)                | 0        |
| SAH 3 h  | 6                    | 0                  | 1                        | 14.3 (1/7)               | 0        |
| SAH 6 h  | 6                    | 0                  | 2                        | 25.0 (2/8)               | 1        |
| SAH 12 h | 6                    | 0                  | 0                        | 0.0 (0/6)                | 1        |
| SAH 24 h | 6                    | 2                  | 2                        | 20.0 (2/10)              | 2        |
| SAH 72 h | 6                    | 0                  | 1                        | 14.3 (1/7)               | 0        |
| Total    | 36                   | 4                  | 6                        | 13.0 (6/46)              | 4        |

SAH, subarachnoid hemorrhage.

Table SII. Rat usage and mortality of experiment 2.

| Groups                    | Usage of the rats, n       |                           | Number of deaths in rats | Mortality, % (n/total n) | Excluded, n |
|---------------------------|----------------------------|---------------------------|--------------------------|--------------------------|-------------|
|                           | Short-term neurobehavioral | Long-term neurobehavioral |                          |                          |             |
| Sham                      | 6                          | 10                        | 0                        | 0.0 (0/16)               | 0           |
| SAH + vehicle             | 6                          | 10                        | 3                        | 15.8 (3/19)              | 1           |
| SAH + NQDI-1 (1.0 µg/kg)  | 6                          | 0                         | 1                        | 14.3 (1/7)               | 0           |
| SAH + NQDI-1 (3.0 µg/kg)  | 6                          | 10                        | 3                        | 15.8 (3/19)              | 1           |
| SAH + NQDI-1 (10.0 µg/kg) | 6                          | 0                         | 0                        | 0.0 (0/6)                | 0           |
| Total                     | 30                         | 30                        | 7                        | 10.4(7/67)               | 2           |

SAH, subarachnoid hemorrhage; NQDI-1,

ethyl-2,7-dioxo-2,7-dihydro-3H-naphtho(1,2,3-de)quinoline-1-carboxylate.

Table SIII. Rat usage and mortality of experiment 3.

| Groups                   | Usage of the rats, n | Number of deaths in rats | Mortality, % (n/total n) | Excluded, n |
|--------------------------|----------------------|--------------------------|--------------------------|-------------|
| Sham                     | 4                    | 0                        | 0.0 (0/4)                | 0           |
| SAH + vehicle            | 4                    | 1                        | 20.0 (1/5)               | 0           |
| SAH + NQDI-1 (3.0 µg/kg) | 4                    | 0                        | 0.0 (0/4)                | 0           |
| Total                    | 12                   | 1                        | 7.7 (1/13)               | 0           |

SAH, subarachnoid hemorrhage; NQDI-1,

ethyl-2,7-dioxo-2,7-dihydro-3H-naphtho(1,2,3-de)quinoline-1-carboxylate.

Table SIV. Rat usage and mortality of experiment 4.

| Groups                   | Usage of the rats, n | Number of deaths in rats | Mortality, % (n/total n) | Excluded, n |
|--------------------------|----------------------|--------------------------|--------------------------|-------------|
| Sham                     | 6                    | 0                        | 0.0 (0/6)                | 0           |
| SAH                      | 6                    | 2                        | 25.0 (2/8)               | 1           |
| SAH + vehicle            | 6                    | 2                        | 25.0 (2/8)               | 0           |
| SAH + NQDI-1 (3.0 µg/kg) | 6                    | 1                        | 14.3 (1/7)               | 0           |
| SAH + Scr siRNA          | 6                    | 2                        | 25.0 (2/8)               | 0           |
| SAH + ASK1 siRNA         | 6                    | 0                        | 0.0 (0/6)                | 0           |
| SAH + BMS-582949         | 6                    | 1                        | 14.3 (1/7)               | 0           |
| SAH + SP600125           | 6                    | 1                        | 14.3 (1/7)               | 1           |
| Total                    | 48                   | 9                        | 15.8 (9/57)              | 2           |

SAH, subarachnoid hemorrhage; NQDI-1, ethyl-2,7-dioxo-2,7-dihydro-3H-naphtho(1,2,3-de)quinoline-1-carboxylate; Scr, scrambled; siRNA, small interfering RNA; BMS-582949, the p38 inhibitor; SP600125, the JNK inhibitor.

Table SV. Overall mortality and exclusion numbers of rats in all experiments.

| Groups | Mortality, %<br>(n/total n) | Excluded, n |
|--------|-----------------------------|-------------|
| Sham   | 0.0 (0/34)                  | 0           |
| SAH    | 15.4 (23/149)               | 8           |

SAH, subarachnoid hemorrhage.